Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02823405 · ClinicalTrials.gov registry record · Phase 1
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma
A Phase 1 study of Melanoma, sponsored by X4 Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 4
- Study locations
NCT02823405 is a Phase 1 study of Melanoma that has completed, run by X4 Pharmaceuticals. The registered enrollment target is 16 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02823405, a Phase 1 study of Melanoma, has completed, sponsored by X4 Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goals of this protocol are 1) to investigate the safety and tolerability of X4P-001 in combination with Keytruda® (pembrolizumab) in patients with advanced melanoma, and 2) to assess serial biopsies of melanoma tumor lesions obtained throughout the study for inflammatory and tumor cell infiltrates. After completion of study treatment, participants with resectable disease will undergo surgery, unresectable participants may continue on pembrolizumab as standard of care.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG X4P-001
Study Locations (4)
Georgia
- Clinical Site - Atlanta
Iowa
- Clinical Site - Iowa City
Texas
- Clinical Site - Houston
Utah
- Clinical Site - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-09-15 |
| Est. Completion | 2018-03-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02823405
The ClinicalTrials.gov registry entry for NCT02823405 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (98% lower). The listed sponsor is X4 Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02823405 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Georgia, Iowa, Texas.
Frequently Asked Questions
What is clinical trial NCT02823405 about?
NCT02823405 is a clinical study titled "X4P-001 and Pembrolizumab in Patients With Advanced Melanoma". The goals of this protocol are 1) to investigate the safety and tolerability of X4P-001 in combination with Keytruda® (pembrolizumab) in patients with advanced melanoma, and 2) to assess serial biopsies of melanoma tumor lesions obtained throughout the study for inflammatory and tumor cell infiltrat...
What is the current status of trial NCT02823405?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-09-15. Estimated completion is 2018-03-15.
What conditions does trial NCT02823405 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT02823405?
The interventions under investigation include: Pembrolizumab (DRUG), X4P-001 (DRUG).
Who is sponsoring clinical trial NCT02823405?
This trial is sponsored by X4 Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02823405 being conducted?
This trial has 4 study locations across Georgia, Iowa, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.